Develops genetic editing and biopharmaceutical solutions, focusing on oncology and other therapeutic areas.
2006
United States
51 - 200 employees
Biotechnology
$25M - 100M in revenue
Not profitable
Total Annual
Revenue & EBITDA
($ B)
Margin as % of revenue
R&D as % of revenue
Analyst consensus vs actuals
($ B)
0.0
▲ 13.5%
0.0
▼ 11.7%
0.1
▼ 7.8%
0.3
2031Not available
Not available
Not available
Available
5 out of 11 incl. management
Not available
Not available
Available
Not available
Not available
Not available
Not available